ACIL issues recommendations to improve insurance transparency and fairness
Government officials, industry leaders, and consumer rights groups called to back reforms
Source: insurancebusinessmag.com
Standard Definitions News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Standard Definitions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Standard Definitions Today - Breaking & Trending Today
Adjuvant Abemaciclib Provides Survival Benefit in Chinese Breast Cancer Population
Abemaciclib plus endocrine therapy delivered sustained survival benefits with a tolerable safety profile when used as adjuvant treatment in Chinese patients with high-risk, hormone receptor–positive, HER2-negative early breast cancer.
Source: onclive.com
ISDA Launches Standard Definitions For The Voluntary Carbon Market
<p><span>ISDA has published new industry documentation for the trading of verified carbon credits (VCCs), as part of a broad effort to support the transition to a green economy by developing robust legal and risk management standards for markets related to environmental, social and governance (ESG) activities.</span></p>
Source: mondovisione.com
ICC lays out roadmap for the future of trade finance | Global Trade Review (GTR)
The International Chamber of Commerce (ICC) has published a framework for the trade finance industry as it grapples with the challenge of better serving smaller businesses. The document, titled Reconceiving the Trade Finance Ecosystem, sets out a road map for digitally connecting and facilitating interoperation among existing trade finance networks through sets of shared standards, ...
Source: gtreview.com
Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021
Share this article Share this article INDIANAPOLIS, March 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC). The PRO analysis included patients in both arms of the study and measured their experiences with side effects, symptoms, and health-related quality of life, in those ...
Source: prnewswire.com